VTA-100 / Vita Therap - LARVOL DELTA

First preclinical results for VTA-100 reported by Vita Therapeutics (Bioworld) - "At the recent International Society for Stem Cell Research meeting, Vita Therapeutics Inc. presented the first preclinical results on VTA-100, a cell therapy consisting of induced pluripotent stem cell (iPSC)-derived satellite cells, for the treatment of limb-girdle muscular dystrophy 2A/R1."

Preclinical • CNS Disorders • Muscular Dystrophy